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The RNA-binding protein (RBP) TAF15 is implicated in amyotrophic lateral sclerosis (ALS). To
compare TAF15 function to that of two ALS-associated RBPs, FUS and TDP-43, we integrate
CLIP-seq and RNA Bind-N-Seq technologies, and show that TAF15 binds to B4,900 RNAs
enriched for GGUA motifs in adult mouse brains. TAF15 and FUS exhibit similar binding
patterns in introns, are enriched in 30 untranslated regions and alter genes distinct from
TDP-43. However, unlike FUS and TDP-43, TAF15 has a minimal role in alternative splicing. In
human neural progenitors, TAF15 and FUS affect turnover of their RNA targets. In human
stem cell-derived motor neurons, the RNA proﬁle associated with concomitant loss of both
TAF15 and FUS resembles that observed in the presence of the ALS-associated mutation FUS
R521G, but contrasts with late-stage sporadic ALS patients. Taken together, our ﬁndings
reveal convergent and divergent roles for FUS, TAF15 and TDP-43 in RNA metabolism.
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A
myotrophic lateral sclerosis (ALS) is a fatal disease
characterized by progressive degeneration of motor
neurons (MNs) in the motor cortex, brainstem and spinal
cord. Although the precise pathogenesis of ALS remains
unknown, aberrant RNA processing appears to be an important
contributing factor. The RNA-binding protein (RBP) TAR
DNA-binding protein 43 (TDP-43) was initially recognized as a
major constituent of pathological ubiquitinated protein
aggregates in the brain and spinal cord tissue of patients with
sporadic ALS (sALS)1,2. Dominant mutations in TDP-43 were
subsequently identiﬁed in ALS patients3–8 with evidence that
these mutations were indeed causative of ALS pathogenesis9.
Shortly thereafter, mutations in the gene encoding another RBP,
fused in sarcoma (FUS, also known as translocated in liposarcoma
or TLS), were identiﬁed in a subset of patients with familial ALS
and sALS10,11. Although mutations in FUS and TDP-43 are
present in only a small fraction of ALS cases, abnormal activity of
FUS and TDP-43 is observed in a large fraction of ALS cases.
The discovery of mutations in the genes encoding TDP-43 and
FUS received much attention as these proteins have strikingly
similar protein domain architectures12. This motivated a search
for more structurally similar RBPs as candidate ALS genes and, as
a result, mutations in TATA box-binding protein (TBP)-
associated factor 15 (TAF15) were identiﬁed in patients with
sALS and familial ALS13,14. FUS and TAF15 belong to the FET
family of heterogeneous nuclear ribonucleoparticle (hnRNP)
proteins, which includes Ewing sarcoma breakpoint region 1. As
the protein structure of TAF15 is similar to those of FUS and
TDP-43 (ref. 13), it was predicted that TAF15 would be
functionally similar to these RBPs. Similar to FUS and TDP-43,
TAF15 is predominantly localized to the nucleus but shuttles to
and from the cytoplasm, participates in transcription, is thought
to affect alternative splicing (AS) and has been found to form
cytoplasmic inclusions in all FUS-FTLD subtypes and in some
sALS patient tissues13,15,16.
Another commonality among TDP-43, FUS and TAF15 is that
the vast majority of ALS-associated mutations identiﬁed in the
genes encoding these RBPs are found in their C-terminal Gly-rich
domains. An emerging hypothesis is that mutations within the
Gly-rich region of these RBPs promote their pathological
aggregation17,18. Aggregation of FUS, TDP-43 and TAF15
proteins is often accompanied by loss of their nuclear
localization; yet it is unclear whether protein aggregation or
mislocalization to the cytoplasm is the initiating pathogenic
event19. In efforts to investigate the normal nuclear function of
these RBPs, comprehensive RNA-binding maps of TDP-43, FUS
and TAF15 in the normal mouse20–22 or human15 central
nervous system (CNS) have been determined. These studies
revealed global roles for TDP-43, FUS and TAF15 in AS and
motif speciﬁcities for TDP-43 and FUS in the CNS. Furthermore,
loss of TDP-43 or FUS expression affects the RNA levels of genes
containing long introns20–22. Our understanding of FUS, TDP-43
and TAF15 function in RNA processing has primarily come from
examining these proteins individually and under different
conditions, making comparisons difﬁcult. This approach has
limited our understanding of how the activities of these RBPs may
converge on common pathways or act in parallel. A systematic
comparison of FUS, TDP-43 and TAF15 to determine their
shared and unique functions in mature and developing neurons
would be valuable in understanding their contribution to
development and ultimately disease.
Here we identify 4,873 RNA targets of TAF15 in the mouse
brain that reveal a TAF15-binding motif. Expanding on our
previous studies21,22, we ﬁnd that FUS and TAF15 exhibit similar
global RNA interaction proﬁles in vivo, but affect a strikingly
small subset of common genes. Unexpectedly, TAF15 inﬂuences a
small fraction of AS events compared with TDP-43 and FUS in
the mouse CNS. In human neural progenitor cells (NPCs), we
ﬁnd that TAF15 and FUS affect the stability of distinct mRNA
populations, many of which are bound by TAF15 and FUS.
Depletion of TAF15, FUS and TDP-43 in human-induced
pluripotent stem cell (iPSC)-derived MNs also affects different
genes. Subsets of TAF15 and FUS-regulated mRNAs, including
ALS-associated genes, are also differentially expressed in spinal
cord MNs dissected from sALS patients and iPSC-derived MNs
from ALS patients harbouring a R521G mutation in FUS. Taken
together, these ﬁndings uncover points of functional convergence
and divergence of FUS, TAF15 and TDP-43.
Results
TAF15 binds RNAs enriched for GGUAAGU motifs in vivo. To
identify in vivo RNA substrates recognized by TAF15, we
performed CLIP (crosslinking immunoprecipitation)-seq in
whole-brain tissue from adult mice using a commercially avail-
able antibody that speciﬁcally recognizes the N terminus of the
TAF15 protein. We isolated RNA from low and high molecular
weight TAF15 protein–RNA complexes (Fig. 1a, bands A and B,
respectively) and converted the RNA into sequencing libraries for
transcript identiﬁcation. No protein–RNA complexes were
immunoprecipitated when using nonspeciﬁc IgG or in the
absence of ultraviolet crosslinking (Supplementary Fig. 1a).
Interactions between TAF15 and FUS have previously been
detected23,24. Therefore, we tested whether TAF15 and FUS
interact post-cell lysis. Uniquely tagged versions of TAF15 and
FUS proteins were expressed separately in HEK293T cells, and
upon mixing lysates from these cell lines we found that V5-tagged
TAF15 immunoprecipitates Myc-tagged FUS (Supplementary
Fig. 1b, lane 10) and vice versa (Supplementary Fig. 1b, lane 14).
This demonstrated that TAF15 and FUS can physically associate
post-cell lysis. For our TAF15 CLIP-seq experiments, the use
of ultraviolet-crosslinked cells and highly stringent lysis and
wash conditions prevented co-immunoprecipitation of FUS
(Supplementary Fig. 1a) and TDP-43 (Supplementary Fig. 1c)
with TAF15, ensuring that FUS-RNA and TDP-43-RNA
complexes were not inadvertently recovered. Given the high
overlap in sequence similarity between the TAF15 target RNAs
isolated from the low (band A) and high (band B) molecular
weight complexes (Supplementary Fig. 1d), the libraries were
combined (Fig. 1b and Supplementary Fig. 1e), resulting in 5.9
million non-redundant sequenced reads that mapped to 13,633
annotated protein-coding pre-mRNAs having more than 10 reads
(5,128,815 reads, 85.8%), noncoding genes (139,382 reads, 2.3%)
and intergenic regions (706,897 reads, 11.8%) in the mouse
genome (mm9).
Using a published cluster-ﬁnding algorithm22, we identiﬁed
47,138 TAF15-binding clusters in 4,873 genes. We applied the
HOMER algorithm to these clusters to discover in vivo TAF15-
binding motifs. The consensus motif GGUAAGU was statistically
signiﬁcantly enriched in TAF15 clusters (Fig. 1c, Po10 535).
Interestingly, this motif is similar to the 50 splice site sequence,
GURAGU (ref. 25); however, enrichment of this motif in both the
coding sequence and the 30 untranslated repeat (UTR) provided
evidence that we did not inadvertently extract the 50 splice site
sequence within introns. Distribution analysis also illustrated that
the TAF15 motif is enriched within the centre of the CLIP
clusters in the transcriptome (Fig. 1d) and also within 30 UTRs
(Fig. 1e). We searched for the TAF15 motif in clustered reads
from published FUS (ref. 21) and TDP-43 (ref. 22) CLIP-seq
experiments and observed that the TAF15 motif was also
enriched in transcriptome-wide FUS CLIP clusters and, to a
lesser extent, in TDP-43 CLIP clusters residing in 30 UTRs
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(Fig. 1d,e). We conclude that TAF15 interacts with binding sites
enriched for a GGUAAGU motif within thousands of genes in vivo.
RNA Bind-n-Seq reveals TAF15 binding to GGUA motif in vitro.
To characterize the in vitro sequence speciﬁcity of TAF15,
we applied RNA Bind-n-Seq (RBNS)26 to recombinant TAF15
and, as a comparison, to recombinant FUS protein. Brieﬂy,
truncated forms of recombinant TAF15 or FUS containing
both the RNA recognition motif and zinc-ﬁnger domain (amino
acids 204–415 for TAF15 and amino acids 235–481 for FUS)
were incubated with an RNA pool consisting of random 20mer
RNAs ﬂanked by short primers used to add adapters for
high-throughput sequencing (Fig. 2a). For FUS, this truncated
region was previously shown to exhibit high afﬁnity for
RNA27. Complementary to in vivo interactions identiﬁed by
CLIP-seq, this method evaluates TAF15 and FUS independently of
its in vivo complex interaction with RNA. For TAF15,
RBNS discovered degenerate G-rich and GU-rich motifs and
notably an (A/G)GGUA motif that resembled the GGUAAGU
motif that was identiﬁed in vivo by CLIP (Fig. 2b). In fact, the
shared GGUA 4mer was signiﬁcantly enriched in hexamers that
were over-represented in both RBNS and TAF15 CLIP-derived
clusters relative to the appropriate control backgrounds (Fig. 2c). In
addition, the same GGUA motif was enriched in the TAF15 clusters
located within 30 UTRs of target genes (Supplementary Fig. 2a).
RBNS applied to FUS domains identiﬁed a similar degenerate G-rich
motif, a GC-rich motif, and a GGUGG motif (bottom motif in
Fig. 2d) that resembled motifs identiﬁed in published in vivo CLIP
studies20,21. A similar evaluation of the GUGG 4mer (or GGUG,
not shown) conﬁrmed enrichment within FUS in vivo CLIP-
seq-derived clusters in the transcriptome (Fig. 2e) and in 30
UTRs (Supplementary Fig. 2b). Interestingly, we found that the
distribution of the GUGG 4mer was also enriched in the hexamers
derived from the TAF15 RBNS experiment (Supplementary Fig. 2c).
Similarly, the GGUA 4mer was enriched in the FUS hexamers
(Supplementary Fig. 2d). Although both of these motifs were
found at a lower level of signiﬁcance in the hexamers derived
from experiments interrogating the other protein, our results
suggest that TAF15 and FUS share some afﬁnity with each other’s
motifs. It is noteworthy that the afﬁnities of TAF15 and
FUS to k-mers containing GGUA and GGUG, although
signiﬁcantly different from background, is relatively weak
compared with previously studied RBPs such as RBFOX2,
MBNL1 and CELF1 (ref. 26). We conclude that TAF15 interacts
with a previously undiscovered GGUA core motif within
signiﬁcantly enriched clusters in vivo. Importantly, our results
demonstrate that the interactions of FUS and TAF15 with
their RNA-binding sites can occur independently of cofactor
associations.
TAF15 interacts with many FUS-RNA targets. Similar to FUS
and TDP-43, TAF15 clusters were predominantly found within
introns (Supplementary Fig. 3a), consistent with previously
published results in HEK293 cells28, mouse neurons and human
brain tissue15. As intronic regions account for a substantial
proportion of nucleotides in transcribed RNA, this distribution
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Figure 1 | CLIP-seq reveals that TAF15 binds GGUAAGU motifs in the mouse brain. (a) Autoradiograph of TAF15 protein–RNA complexes from the
mouse brain immunoprecipitated with an antibody against TAF15 (left panel). RNA residing in the regions outlined by the red boxes was recovered for
sequencing. TAF15–RNA complexes migrated at the expected size and were efﬁciently recovered because little protein remained in post-
immunoprecipitation lysate (right panel, middle lane). (b) Flow chart illustrating CLIP-seq reads analysed to deﬁne TAF15 clusters. (c) De novo sequence
motifs enriched above background within the transcriptome or speciﬁc genic regions with associated binomial P values. (d) Positional distribution of the
TAF15 motif GGUAAGU within TAF15 (red), FUS (green) or TDP-43 (purple) CLIP clusters. Inset graph shows the per cent enrichment of the TAF15 motif
GGUAAGU within TAF15 targets (‘Target’) or within the transcriptome (‘Background’). (e) Positional distribution analysis of the TAF15 motif GGUAAGU as
in d but speciﬁcally within CLIP clusters residing in 30 UTRs. Inset graph shows the per cent enrichment of the TAF15 motif GGUAAGU within the 30 UTRs
of TAF15 targets (‘Target’) or within the 30 UTRs of the transcriptome (‘Background’).
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was expected and similar to other predominantly nuclear-
localized RBPs such as RBFOX1 and NOVA1 (Supplementary
Fig. 3a). Unlike TDP-43, we found that TAF15 and FUS binding
was signiﬁcantly enriched in the 30 UTR, akin to RBFOX1 and
NOVA1 that also have proposed 30 end formation roles29,30
(Fig. 3a). To illustrate this, the 30 UTR of the neurobeachin
(Nbea) transcript, encoding a protein involved in synaptic
function and autism31, is enriched for TAF15 and FUS binding
(Fig. 3b). FUS had a similar binding proﬁle as TAF15, whereas
TDP-43 bound an intronic region upstream of the penultimate
exon, but with no cluster in the 30 UTR (Fig. 3b).
We found that targets of RBFOX1 and NOVA1 do not overlap
with TAF15 target genes (Supplementary Fig. 3b). In contrast, the
majority of FUS (98%) and TDP-43 (86%) target RNAs were also
TAF15 targets (Fig. 3c). For genes that were targets of both
TAF15 and FUS, 38% had at least one binding site that
overlapped between TAF15 and FUS (Supplementary Fig. 3c).
Our results indicate that TAF15 and FUS bind to the same genes
with close proximity, consistent with our ﬁndings that the GUGG
motif preferred by FUS was enriched in TAF15 CLIP clusters and
the GGUA motif preferred by TAF15 was also enriched in FUS
CLIP clusters (Supplementary Fig. 2c,d). TAF15 also exhibited a
‘saw-tooth’-like pattern of deposition within genes containing
long introns, such as the glutamate receptor delta-1 subunit
precursor gene (Grid1), similar to FUS, but dissimilar to TDP-43
(ref. 21; Fig. 3d). We conclude that TAF15 and FUS binding are
enriched in the 30 UTRs of target genes and both harbour the
same ‘saw-tooth’-like proﬁles in long introns.
Distinct roles of TAF15, FUS and TDP-43 on gene expression.
To identify TAF15-regulated RNAs, single-stranded antisense
oligonucleotides (ASOs) complementary to TAF15 RNA or
non-targeting control ASOs (Control) were delivered into the
adult mouse striatum. TAF15 mRNA and protein were depleted
by at least 90% in mice treated with TAF15-targeting ASOs
(Fig. 3e). RNA extracted from striata of three mice was subjected
to strand-speciﬁc RNA sequencing (RNA-seq) library generation
and sequencing. On average, 24.8 million reads were obtained for
each library, of which 86% mapped to the mouse genome (mm9).
We identiﬁed 194 and 91 genes (Supplementary Data 1) that were
signiﬁcantly (Po0.05) downregulated (Fig. 3f) and upregulated
(Fig. 3g), respectively, when TAF15 protein was depleted. To
examine overlapping and unique effects of TAF15, FUS and
TDP-43 on RNA expression, we re-analysed RNA-seq data sets in
which FUS and TDP-43 were depleted from the mouse striatum
in the same manner as TAF15 (refs 21,22). Although Fus and
Tdp-43 expression remained unchanged upon TAF15 depletion,
the Taf15 mRNA level appears to be slightly increased upon FUS
depletion (Supplementary Fig. 3d). Similar to FUS and TDP-43
(ref. 21), we found that genes downregulated by loss of TAF15
exhibited exceptionally long introns (Supplementary Fig. 3e).
Despite this similar trend in regulation, there was a poor overlap
between the differentially regulated genes such that by our
conservative re-analysis, only eight genes (including Park2, Nrxn1
and Kcnip4) were commonly downregulated (Fig. 3f) and no
genes were commonly upregulated (Fig. 3g). To distinguish
between direct and indirect effects of RBP binding on gene
expression, we measured the fraction of affected genes that were
directly bound as determined by CLIP-seq. A signiﬁcantly higher
proportion of genes downregulated upon TAF15 or TDP-43 loss
were direct targets of that RBP (Fig. 3h). Closer examination
revealed that this association remains signiﬁcant for the subset of
downregulated genes that exhibited TAF15 (and to some extent
TDP-43) binding in the 30 UTR (Supplementary Fig. 3f). In
support of this result, genes that were downregulated upon
TAF15 loss were more likely to contain the TAF15 ‘GGUAA’
motif in their 30 UTRs or introns (Supplementary Fig. 3g). Genes
that were upregulated or were unaffected upon loss of FUS,
a
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Figure 2 | RNA Bind-n-Seq conﬁrms enrichment for GGUA motifs in
RNAs that bind TAF15 in vitro. (a) Experimental overview of RBNS.
Truncated versions of TAF15 and FUS (highlighted in red and green,
respectively) were tagged and incubated at different concentrations with a
diverse pool of RNA oligonucleotides ﬂanked by adapters. The tagged
proteins were retrieved with streptavidin-coated beads and bound RNAs were
sequenced. Input RNA was sequenced in parallel to quantify the proportions
of bound RNA molecules. (b) RNA-binding preferences for truncated TAF15
shown as motif logos made from aligning RBNS 6mers weighted by
their enrichments. Motif proportions were determined by summing the
enrichments of each motif’s aligned 6mers. (c) Scatter plot correlating the
per cent enrichment above background of 6mers in TAF15 mouse brain
CLIP-seq versus TAF15 RBNS R Z-scores. Red dots represent all signiﬁcant
6mers containing the GGUA motif. Histograms show normalized distributions
of 6mers containing (red) or not containing (black) the GGUA motif in CLIP-
seq (right) or RBNS (top). P values shown are computed by a Kolmogorov–
Smirnov statistic. (d) RNA-binding preferences for truncated FUS as in b.
(e) Scatter plot and histogram analyses are as described in c using FUS
mouse brain CLIP-seq versus FUS RBNS R Z-scores. Green dots represent all
signiﬁcant 6mers containing the GUGG motif.
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TAF15 or TDP-43 were generally not binding targets (Fig. 3i,j).
Thus, we conclude that, although FUS, TAF15 and TDP-43 bind
many of the same targets, only a small fraction of genes are
similarly affected by loss of each of the three RBPs.
TAF15 has a marginal role in AS. Using splicing-sensitive
microarrays, we detected 182 AS events that were altered upon
TAF15 depletion in the mouse striatum (Fig. 4a). Although
TAF15, TDP-43 and FUS proteins were reduced to similar levels,
we observed fewer TAF15-dependent splicing events (n¼ 187)
compared with the number of splicing events altered by loss of
FUS (n¼ 327) or TDP-43 (n¼ 690; Supplementary Data 2).
There was little overlap in AS events altered by loss of TAF15,
FUS or TDP-43 (Fig. 4b and Supplementary Fig. 4a). This sug-
gests that, despite their high similarity in domain architecture and
documented interactions with splicing factors32,33, FUS and
TAF15 have distinct impacts on AS.
An AS event altered by TAF15 is exon 5 of the glyceropho-
sphocholine phosphodiesterase 1 gene (GPCPD1; Fig. 4c), which
was included upon TAF15 knockdown and harbours binding sites
for TAF15 and FUS downstream of the 50 ﬂanking exon
(indicated by an arrow). Another example, exon 24 in the
calcium-activated potassium channel subunit alpha-1 gene
(Kcnma1; Fig. 4d), was also included upon TAF15 loss and
contained nearby TAF15- and FUS-binding sites (indicated by an
arrow). Although TDP-43-binding sites were present near these
exons, they were distinct from TAF15- and FUS-binding sites
(Fig. 4c,d). A previous study reported that knockdown of TAF15
promoted the exclusion of exon 19 of the N-Methyl-D-Aspartate
Receptor Subunit NR1 (Grin1) gene in mouse neurons15. TAF15-
and FUS (but not TDP-43)-binding sites were present proximal
to this exon, but depletion of TAF15 did not cause a statistically
signiﬁcant change (P¼ 0.106) in the exclusion of exon 19 of
Grin1 in the mouse striatum (Supplementary Fig. 4b). This does
not appear to be because of differences in tissue speciﬁcity as
depletion of TAF15 in the mouse brain or spinal cord
(Supplementary Fig. 4c) also had no signiﬁcant effect on Grin1
exon 19 splicing (Supplementary Fig. 4d). We conclude that in
contrast to our and others’ previous ﬁndings with FUS and
TDP-43 (refs 20–22,34) and a study regarding TAF15 (ref. 15),
TAF15 alters the splicing of a relatively small subset of genes, of
which the majority (70%) are distinct from those regulated by
either FUS or TDP-43.
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TAF15 and FUS affect mRNA stability in neural progenitors.
To evaluate the role of TAF15 in early neuronal development, we
used human NPCs differentiated from iPSCs in which TAF15
protein levels and, for comparison, FUS protein levels, were
individually depleted by lentiviral short hairpin RNAs (shRNAs;
Fig. 5a,b). As TAF15 has a relatively minor role in AS, we
investigated a potential role for TAF15 in RNA stability. NPCs
were treated with the transcriptional inhibitor Actinomycin D for
varying times, after which total RNA was collected and prepared
for RNA-seq libraries (Fig. 5a). Half-life measurements were
determined from a regression-based analysis of gene expression,
assuming ﬁrst-order decay kinetics. For each shRNA treatment,
the median value for the coefﬁcient of determination (R2)
describing the log-linear ﬁt across the time course for each gene,
across all genes, was 0.54; this value was signiﬁcantly higher
(PB0, by Kolgomorov–Smirnov two-tailed test) than the value
(0.12) obtained by randomly shufﬂing the expression values for
each time point within each gene (Fig. 5c and Supplementary
Fig. 5a,b). To minimize false positives, we evaluated genes for
which the R2 value was greater than 0.6. We identiﬁed 299 and
330 genes that were highly stabilized (increased half-life), as well
as 132 and 44 genes that were highly destabilized (decreased
half-life) upon loss of TAF15 and FUS, respectively (Fig. 5d,
Supplementary Data 3).
We arbitrarily selected mRNAs that were most stabilized or
destabilized by loss of TAF15 (marked by asterisks in Fig. 5e) and
performed RNA immunoprecipitation followed by quantitative
reverse transcriptase PCR (qRT–PCR) to determine whether
these mRNAs were directly bound by TAF15 and FUS. TAF15
bound to most mRNAs (four of ﬁve) that were stabilized upon
loss of TAF15 (URB1, SNX9, CLN8 and SMURF2; Fig. 5f), of
which URB1, CLN8 and SMURF2 also exhibited FUS interactions.
In addition, TAF15 bound to most mRNAs (four of ﬁve) that
were destabilized upon loss of TAF15 (ATXN7L3B, PRKRIR,
RAPGEF1 and CGGBP1; Fig. 5g). Notably, FUS bound to all these
mRNAs (including TCERG1); however, FUS depletion did not
appear to have an effect on mRNA stability of these transcripts
(Fig. 5e and Supplementary Data 4). ANAX2 and TIAL1, whose
mRNAs were unaltered by TAF15 loss, were also examined for
TAF15 and FUS binding (Supplementary Fig. 5c). A gene
ontology (GO) analysis of genes affected at the mRNA stability
level upon TAF15 knockdown revealed statistical enrichment for
genes implicated in DNA-dependent transcription control
(Po10 26; Supplementary Data 5). An example of TAF15
mRNA turnover target involved in transcriptional control and
also neurological diseases is the CGG-binding protein 1
(CGGBP1), which binds to CGG repeats in the promoter of the
fragile X mental retardation 1 (FMR1) gene resulting in reduced
expression35. We conclude that TAF15 and FUS control mRNA
turnover in NPCs of distinct mRNA substrates.
TAF15 and FUS affect different genes in human MNs. To
discover the molecular events modulated by loss of TAF15, FUS
and TDP-43 in an ALS-relevant cell type, we generated MNs
from wild-type human iPSCs using a directed differentiation
protocol36. Brieﬂy, a combination of SMAD signalling inhibitors,
Noggin, and the ALK5 inhibitor, SB431542, was used to yield a
population of cells enriched for HB9, ISLET1 and TUJ1 (neuron-
speciﬁc class III)-positive MNs with a minor fraction of OLIG2-
positive oligodendrocytes (Fig. 6a,b). We subjected the MNs to
lentivirus-packaged shRNAs targeting TAF15, FUS or TDP-43.
As our in vivo ﬁndings indicated that TAF15 and FUS bind to
similar RNA substrates, we also simultaneously depleted FUS and
TAF15. Mature RNA and protein levels (Fig. 6c,d and
Supplementary Fig. 6a) of the targeted RBPs were signiﬁcantly
reduced and TAF15 and FUS protein levels did not exhibit
reproducible changes (either up or down) in FUS and TAF15
depletions, respectively (Supplementary Fig. 6a). Reduction of
TAF15, FUS or TDP-43 alone or in combination (TAF15 and
FUS) in iPSC-derived MNs did not cause noticeable changes in
cell morphology or death. We generated RNA-seq data from
these cells, obtaining an average of 32.4 million uniquely mapped
reads.
Similar to our in vivo depletion studies, we observed a minor
overlap in the genes downregulated (61 genes) or upregulated
(6 genes) upon loss of all three RBPs (Fig. 6e and Supplementary
Data 6). In contrast to our ﬁndings in the adult mouse striatum,
introns within downregulated genes affected by loss of TAF15
and FUS in MNs were not signiﬁcantly longer than upregulated
or unaffected genes (data not shown). Expectedly, B76 and 85%
of the genes in the FUS-only and TAF15-only knockdown
experiments were also downregulated in the double knockdown.
However, we found that a subset of genes (n¼ 144) were
downregulated only upon combined loss of TAF15 and FUS in
human MNs (Fig. 6f), indicating a potential redundancy between
TAF15 and FUS in controlling gene expression. These genes that
were downregulated upon combined TAF15 and FUS loss were
enriched for GO terms, reﬂecting extracellular cellular matrix
composition, cell proliferation, wound healing and cytokine
activity.
Genes altered by RBP loss are akin to ALS-linked FUS mutant.
To investigate whether the molecular changes observed upon loss
of FUS, TAF15 or both proteins were relevant to ALS patho-
genesis, we obtained ﬁbroblasts from two ALS patients with the
causative R521G mutation in FUS. The ﬁbroblasts were repro-
grammed into iPSCs and subjected to cellular, molecular and
genetic characterization to conﬁrm that they are pluripotent
(Supplementary Fig. 6b), exhibit a normal karyotype and harbour
the presence or absence of the mutation at nucleotide position
1,561 (Supplementary Fig. 6c). Three individual clones from two
FUS R521G patient-derived iPSC lines (two clones were from one
line) and two control iPSCs (from healthy, age-matched
non-mutant individuals) were directly differentiated to MNs.
RNA isolated from these cells were subjected to RNA-seq library
preparation and sequencing to obtain an average of 20 million
reads, of which 90% mapped uniquely to the human genome
(hg19). To ensure that the differentiation process yielded MNs at
similar stages of differentiation and similar subtypes of cells, we
compared expression of a panel consisting of genes representing
housekeeping, astrocyte, oligodendrocytes, neural precursor and
neuronal subtypes. The similarities in expression proﬁles among
the MN cell lines conﬁrmed that differentiation of the iPSC lines
was consistent and hence enabled downstream comparative
analysis (Supplementary Fig. 6d). We identiﬁed 901 down-
regulated and 805 upregulated (Supplementary Data 7) genes that
were differentially affected in the FUS R521G MNs compared
with wild-type control MNs. Interestingly, although the majority
of mutant-dependent gene expression changes were unique, there
existed statistically signiﬁcant overlaps in the genes down-
regulated in the FUS R521G MNs (relative to control) with genes
downregulated upon loss of FUS (Po10 9) or TAF15
(Po10 3; Fig. 6g). Importantly, this overlap increased in num-
ber when we compared the genes affected by simultaneous
depletion of both FUS and TAF15 (Po10 22; Fig. 6g). In
contrast, we observed no signiﬁcant overlap in genes upregulated
by any condition (Fig. 6g). Overall, these ﬁndings are consistent
with our observations that FUS and TAF15 are redundant in their
effects on molecular targets and implies a partial loss of molecular
function by the FUS R521G mutation.
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Downregulated genes correlate with a sALS RNA signature. To
obtain insights into whether the genes affected by loss of ALS-
associated RBPs resemble disease-speciﬁc RNA signatures, we
turned to a RNA-seq data set generated from laser-capture
microdissected spinal cord samples from sALS patients who had
bulbar or arm onset of disease that was caudally progressing and
thus had abundant residual MNs in the lumbar region at the time
of death37. The RNA-seq data set consisted of samples from 13
sALS and 9 control patients. In all, 3,876 genes were signiﬁcantly
differentially regulated, of which 71% and 29% were upregulated
and downregulated, respectively, in the sALS patient compared
with normal samples (Supplementary Data 8). The differentially
expressed genes were effectively able to separate the diseased
patients from the control patients (Supplementary Fig. 6e). Next,
we tested the hypothesis that ALS RBP-mediated RNA changes
resemble the RNA signature that distinguishes sALS and normal
dc
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samples. For all the comparisons performed, we observed a
signiﬁcant overlap (Po0.05, hypergeometric test) in genes that
were upregulated in sALS samples and downregulated in FUS,
TAF15, TDP-43, or FUS and TAF15 double knockdowns
(Supplementary Fig. 6f). We also observed a signiﬁcant inverse
correlation of signiﬁcantly changing genes between sALS samples
and FUS, TDP-43 or FUS and TAF15 double knockdowns
(Fig. 6h, R2 between  0.14 and  0.32, Po0.05), but not
between sALS samples and the FUS R521G mutant MNs
(Supplementary Fig. 6g). Despite the divergent sets of regulated
genes whose mRNA levels are dependent on ALS-associated
RBPs, we found that 2,747 genes were upregulated in sALS
patient samples. Unlike in vitro differentiated MNs, the sALS
patient samples represent more mature MNs at a late stage of
disease progression. Our ﬁndings indicate that in late-stage sALS
patient samples with TDP-43 pathology37, a subset of genes that
are separable from those found in ALS iPSC-derived FUS R521G
MNs, are abnormally higher compared with control patients.
Among the commonly differentially regulated genes between
knockdown and sALS samples, GO terms for extracellular space
and matrix organization were statistically enriched (Po0.01).
Discussion
Genetic and clinical evidence strongly supports causative roles for
FUS, TDP-43 and TAF15 in ALS. Here we identify common and
unique pathways normally controlled by these proteins utilizing
diverse in vitro and in vivo neuronal systems (Supplementary
Fig. 7). In the adult mouse brain, we identiﬁed TAF15-binding
sites within B4,900 RNA substrates, and a GGUAAGU TAF15-
binding motif not reported in previous studies15,28. We used
RBNS technology to conﬁrm a GGUA motif that was enriched
within in vivo TAF15-binding sites. Together, we conclude that
TAF15 and FUS can interact with their RNA motifs within in vivo
RNA substrates without requiring complex cofactor associations.
Overall, the RNA-binding pattern of TAF15 resembled that of
FUS, but was distinct from TDP-43, even when all three RBPs
targeted the same genes. TAF15 and FUS exhibited saw-tooth-like
binding patterns on long introns, a pattern reminiscent of
co-transcriptional splicing38. Genes downregulated upon loss of
either TAF15 or FUS contained exceptionally longer introns.
In addition, TAF15- and FUS-binding sites were also over-
represented within 30 UTRs, possibly reﬂecting 30 end processing
functions such as RNA turnover, transport and translation.
Upregulation of genes upon FUS and TAF15 loss is likely a
secondary effect as these genes are generally not targets. Lastly,
unlike TDP-43 and FUS, loss of TAF15 appeared to have a minor
impact on AS in the adult mouse brain.
In models of early human neuronal development, we identiﬁed
that TAF15 and FUS affected the mRNA turnover of distinct
subsets of RNA targets in human neuronal progenitor cells.
Furthermore, loss of FUS, TAF15 or TDP-43 in human MNs
derived from the same cells resulted in distinct changes in gene
expression for each RBP. In addition, simultaneous depletion of
FUS and TAF15 resulted in the downregulation of hundreds of
additional genes. FUS and TAF15 have been shown to interact
with each other23,24 (Supplementary Fig. 1b) as well as other
common proteins such as RNA Pol II (refs 39,40), spliceosome
machinery24,32,33 and transcription factors41. One possibility is
that if FUS is unable to recruit regulatory factors to an RNA
target, this function may be compensated for by TAF15.
To gain insight into disease, we compared the results of our
loss-of-function studies to two models of ALS. The ﬁrst model is
MNs from ALS patients carrying the pathogenic FUS R521G
mutation. Expression of FUS R521G from the mouse MAPT locus
has been recently reported to cause neuronal toxicity in neurons
of mice42. Previously, FUS R521G was also associated with a
partial loss-of-function in RNA regulation in mouse spinal
cords43. We did observe a small yet signiﬁcant overlap in genes
downregulated upon loss of TAF15, FUS or both proteins, and
genes altered by FUS R521G. This overlapping set of genes may
reﬂect the partial loss-of-function properties of FUS R521G
(ref. 43). As mRNAs downregulated upon loss of these RBPs
in the mouse brain are often direct binding targets of those RBPs,
we speculate that the FUS R521G mutation, which causes
cytoplasmic FUS mislocalization, resembles a partial loss-of-
function of the RBPs in a model of early development. Never-
theless, the majority of expression changes caused by FUS R521G
were mutant-speciﬁc such that they did not overlap with genes
altered by loss of TAF15, FUS or both proteins. One
interpretation is that these FUS R521G-speciﬁc gene changes
may contribute the pathological, gain-of-function activities of
mutant FUS that was observed to cause MN dysfunction in
mice42.
To model late-stage ALS disease we utilized RNA-seq data
obtained from spinal cord samples collected postmortem by laser-
capture microdissection from sALS patients. These samples
harboured ubiquinated TDP-43 cytoplasmic inclusions and were
from patients with no mutations in known ALS-causative genes,
including FUS, TDP-43 or TAF15. Intriguingly, our comparisons
of RNA signatures revealed an inverse correlation in a separate set
of genes that were upregulated in the sALS samples but were
downregulated upon loss of ALS-associated RBPs in in vitro-
derived MNs. This indicates that these genes, whose levels
are normally dependent and maintained by FUS, TAF15 and
TDP-43, are aberrantly higher in late-stage ALS. A possible
mechanism for gene upregulation is the breakdown of negative
feedback loops as is observed for the effect of TDP-43 on its own
expression44,45. We did not, however, observe a difference in
TDP-43 mRNA levels between sALS and control neurons.
Figure 5 | Loss of TAF15 or FUS affects mRNA stability in human neural precursor cells. (a) Schematic of workﬂow. (1) Human iPSCs were differentiated
into NPCs and stained for neuronal lineage markers DCX (left, green), NESTIN (right, red) and SOX2 (right, green) to conﬁrm differentiation. 4,6-Diamidino-2-
phenylindole (DAPI; blue) was used to locate nuclei. Scale bar, 25mm. (2) NPCs were infected with virus expressing shRNAs against TAF15 or FUS and then
treated with Actinomycin D for indicated duration. (3) Poly(A)-selected RNA was converted into libraries for sequencing, and sequencing reads were used to
calculate mRNA half-lives. (b) Validation of shRNA-mediated knockdown of FUS or TAF15 in NPCs by western blot analysis. Representative western blot is
shown from one replicate with quantiﬁcations from biological triplicate knockdown experiments. (c) For each gene, the coefﬁcient of determination (R2)
reﬂecting the ﬁt of the RPKM values to a log-linear regression was computed. The cumulative distribution functions of the R2 values for all genes in the TAF15
depletion experiment are depicted for real and shufﬂed values. (d) Table displaying the number of mRNAs whose half-lives were destabilized, stabilized or
unchanged by depletion of TAF15 or FUS. Half-life changes, measured as log2 (knockdown/control), that were greater than 1 were considered. (e) Heatmap of
normalized RPKMs for stabilized and destabilized mRNAs upon shRNA-mediated knockdown of TAF15 or FUS. RPKMs are normalized for each gene to its
RPKM at time 0. An asterisk indicates that the gene was examined for binding in f. (f) RNA immunoprecipitation was performed using antibodies against IgG
(Control), TAF15 and FUS in NPCs. The relative fold change compared with the IgG control for genes that are stabilized by TAF15 loss was determined with
qPCR. Values are means±s.d. for biological duplicates. Asterisk denotes a signiﬁcant difference compared with IgG by Student’s t-test where **Po0.005 and
*Po0.05. (g) RNA immunoprecipitation analysis as in f for mRNAs that were destabilized upon TAF15 loss.
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Figure 6 | Comparison of MN RNA signatures upon TAF15, FUS or TDP-43 loss to two models of ALS. (a) Schematic of workﬂow to reprogramme iPSCs
and to differentiate into MNs. (b) Immunoﬂuorescence of human iPSC-derived MNs for MN marker HB9 (green), post-mitotic neuronal marker TUJ1
(green), neural stem cell marker ISLET1 (red) and oligodendrocyte marker OLIG2 (red). DAPI stain marks cell nuclei (blue). Scale bar, 25 mm. (c) qRT–PCR
and (d) western blot validation of shRNA-mediated depletion of TAF15, FUS and TDP-43 in MNs. Error bars represent s.d. from biological duplicate
experiments. (e,f) Venn diagrams showing overlap of up- and downregulated genes in MNs upon depletion of TAF15, TDP-43, FUS or, simultaneously, FUS
and TAF15 (FUSþTAF15). (g) Venn diagrams showing overlap of up- and downregulated genes between MNs with the FUS R521G mutation and
knockdown of TAF15, FUS or FUSþTAF15. Statistical signiﬁcance was determined by a hypergeometric test using genes expressed in MNs as background.
(h) Scatter plots comparing gene expression changes (log2 RPKM) in MNs from sALS patient samples compared with loss of TAF15, FUS, TDP-43 or
FUSþTAF15. Each quadrant of a scatter plot shows genes (red dots) and gene counts (N, in red) that are signiﬁcantly changing in sALS and RBP depletion
experiments. Genes from a randomly ordered comparison are also shown (black dots) along with gene counts (N, in black). R2 and P values from linear
regression analyses of genes signiﬁcantly changing in both sALS and RBP knockdown experiments are shown.
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Another plausible scenario is that in late stages of the disease,
cytoplasmic inclusions of TDP-43 lead to stabilization of
trapped, cytoplasmic RNA targets. Future studies to identify the
mislocalized RNA targets in cytoplasmic bodies that are protected
from degradation, such as stress granules, may yield further
insight into disease-relevant targets at late stages in the disease.
In summary, our study delineates convergent and divergent
RNA-processing functions of ALS-associated FUS, TAF15 and
TDP-43 in normal and disease settings. Our comprehensive
results shed light on multiple and distinct pathways by which
these RBPs regulate gene expression in diverse neuronal systems
and provide a framework for how they relate to ALS and other
neurodegenerative diseases.
Methods
Injections of ASO in mice. Sterotaxtic injections of ASO complementary to
TAF15 were performed in 8-week-old female C57Bl/b mice to deplete TAF15.
ASOs were delivered speciﬁcally to the striatum or brain/spinal cord by intrastriatal
(12.5 mg) or intracerebroventricular injection (300 mg), respectively, as described
previously21,46. Female mice were regularly monitored for 14 days until being killed
and the tissues were harvested and frozen in TRIzol (Invitrogen). Control
mice received a control ASO without any known target in the mouse genome
under the same conditions. The ASOs were phosphorothioate ‘gapmers’ with
sequences as follows (capitalized nucleotides containing 2±-O-(2-methoxy)ethyl
modiﬁcations): GGTCTcctccatagcTGCCT (TAF15; brain and striatum),
TGGCAatattttacaACGCA (TAF15; spinal cord) and CTCAGTAACATTGA
CACCAC (Control). All procedures were performed using a protocol approved by
the Institutional Animal Care and Use Committee of Ionis Pharmaceuticals and the
University of California at San Diego.
Generation of neural precursor cells and MNs. Human iPSCs derived from
dermal ﬁbroblast cells of a healthy individual (RRN08) were induced into neural
precursor cells using a pan-neuronal protocol as previously described21. Brieﬂy,
stem cells were grown on Matrigel-coated plates (BD) in mTeSR1 growth media
(Stem Cell Technologies). Stem cell colonies were grown on ultra low-attachment
plates in DMEM/F12 þ GlutaMAX supplemented with N2 and FGF-2
(20 ngml 1). After 1 week, neural rosettes were manually picked, replated and
maintained in DMEM/F12 þ GlutaMAX supplemented with N2, B27 and FGF-2
(20 ngml 1).
Generation of human MNs. Human MNs used in the shRNA knockdown
experiments were differentiated from iPSCs (CVB) using a protocol modiﬁed from
(ref. 36). Brieﬂy, human iPSCs were maintained in hEB Media (Knockout D-MEM
þ 10% Knockout Serum Replacement (Life Technologies) þ 10% Plasmanate
(Biocare) þ GlutaMAX þ NEAA (Life Technologies) and supplemented with
10mM SB431542 and 1 mM Dorsomorphin dihydrochloride (Tocris) on feeder-free
dishes. Cells were maintained in SB431542 and Dorsomorphin until day 18 of
differentiation. On days 4, 5 and 6 of differentiation, hEB media were mixed with
N2 Base media (D-MEM/F12 þ GlutaMAX, 1% N2 Supplement þ 4.5mM
D-Glucose, 0.05mM Ascorbic Acid (Sigma)) at a ratio of 70:30, 50:50 and 50:50,
respectively. On days 7 and 8 of differentiation, cells were maintained in 50:50
combination of hEB media and maturation media (D-MEM/F12 þ GlutaMAX, 2%
N2 Supplement, 4% B27 serum-free supplement (Invitrogen), 9.0mM D-Glucose
and 0.1mM ascorbic acid (Sigma)) supplemented with 2 ngml 1 each of ciliary
neurotrophic factor, brain-derived neurotrophic factor and glial cell-derived
neurotrophic factor (Peprotech). From days 7 to 22 of differentiation, cells
were treated with 200 nM Smoothened Agonist (SAG; EMD Biosciences) and
1.5 mM retinoic acid (Sigma). On day 18, cells were dissociated using Accutase
and transferred to dishes coated with Poly-D-Lysine (Sigma) þ Laminin
(Life Technologies) and maintained in maturation media supplemented with
retinoic acid and SAG. On day 22, cells were maintained in maturation media
containing 2 mM DAPT (Tocris). On day 26, cells were maintained in maturation
media only. Throughout the differentiation protocol media was changed daily. The
identity and purity of MNs were analysed by immunoﬂuorescence for markers of
stem cells, MNs, astrocytes and glial cells.
Generation of MNs from ﬁbroblast-derived iPSCs. Adult human primary
ﬁbroblasts were obtained by Franca Cambia, Edward Kasarskis and Haining Zhu
(University of Kentucky). Informed consent was obtained from all subjects before
sample collection. The use of patient ﬁbroblasts for research was approved by the
University of Kentucky Institutional Review Board (IRB 05-0265). Brieﬂy, adult
human primary ﬁbroblasts were cultured at 37 C and 5% CO2 in DMEM sup-
plemented with 10% fetal bovine serum (FBS), NEAA and L-glutamine. To generate
iPS cells, control and ALS patient ﬁbroblasts were transduced with the CytoTune
iPS Sendai Reprogramming Kit, as described in the manufacturer’s protocol
(Invitrogen). Colonies were manually passaged on Matrigel-coated plates and
grown in mTeSR1 growth media. After several passages, colonies were expanded
using Accutase (Innovative Cell Technologies) and grown as a monolayer before
differentiation. MN differentiation was performed as described above with the
following modiﬁcations: CHIR99021 (Tocris) was added at 4 mm until day 7 and
the cells were either ﬁxed for immunostaining or harvested for RNA in TRIzol
(Life Technologies) 35 days post-neural induction. Three ALS patient lines GY6.2,
GY7.3 and GY7.6 are referred to as FUS R521G Line 1, Line 2 and Line 3,
respectively, and two wild-type sibling control lines KIN1ALS17.3 and
KIN1ALS17.4 are referred to as wild-type sibling control Line 1 and Line 2,
respectively.
Lentiviral infections and transfections. Lentiviral shRNA constructs
(Open Biosystems) complementary to human TAF15 (TRCN0000020140,
TRCN0000020141 or TRCN0000020143), human FUS/TLS (TRCN0000010450,
TRCN0000039824 or TRCN0000039825) and human TDP-43 (TRCN0000016038)
in the pLKO.1 vector system were used to produce lentivirus as previously
described47. Virus produced from a pLKO.1 construct containing a control
sequence was used as the control. At 60–70% conﬂuency, NPCs were infected with
virus (multiplicity of infection¼ 3) for 24 h, followed by a complete media change
and further incubation for 72 h until cells were either collected and frozen in
TRIzol (Invitrogen) or pelleted and frozen in liquid nitrogen for RNA and
protein analyses, respectively. For lentiviral infection of MNs, media containing
virus (multiplicity of infection¼ 5) were added to cells on day 28 of the MN
differentiation protocol. After 24 h, a complete media change was performed and
cells incubated for an additional 48 h. A second round of infection, similar to the
ﬁrst, began on day 31. On day 34 of MN differentiation, corresponding to a 6-day
exposure period to shRNA expression, cells were either collected and frozen in
TRIzol (Invitrogen) or pelleted and frozen in liquid nitrogen for RNA and protein
analyses, respectively. For transfection of HEK293T cells, cells were plated in
DMEM high-glucose media (Life Technologies) supplemented with 10% FBS. Cells
were transfected with plasmid expressing human FUS-Myc cloned into pcDNA5 or
TAF15-V5 cloned into pEF5-DEST using FuGENE 6 (Promega) according to the
manufacturer’s protocol for 24 h and then harvested for protein analysis.
CLIP-seq library preparation and sequencing. Brains from 8-week-old female
C57Bl/6 mice were rapidly dissociated by forcing the tissue through a cell strainer
with a pore size of 100 mm (BD Falcon) before ultraviolet crosslinking. CLIP-seq
libraries were constructed as previously described47 using 10mg of a polyclonal
antibody against TAF15 (300A-308, Bethyl Laboratories). Libraries were subjected
to sequencing on a HiSeq2000 platform for 50 cycles. For each CLIP-seq library,
the brain of one mouse was used.
Computational analysis of CLIP-seq experiments. CLIP-seq alignment and peak
calling were performed as previously described21. Brieﬂy, reads with the sequencing
adapter or homopolymeric runs were trimmed and then mapped to the repeat-
masked mouse genome (mm9) using Bowtie (version 0.12.2) with parameters
 q  p 4  e 100  a m 10  best–strata. Reads that were ﬂagged as PCR
duplicates were removed. Signiﬁcant clusters of reads were identiﬁed using a
Poisson distribution with two different frequencies to determine a P value. First, a
transcriptome-wide frequency was calculated by dividing the total length of all
pre-mRNAs by the total number of CLIP reads mapping to the whole pre-mRNA
transcriptome. Second, a gene-speciﬁc frequency was calculated by dividing the size
of the gene-speciﬁc pre-mRNA by the total number of CLIP reads mapping to that
gene-speciﬁc pre-mRNA. A signiﬁcant cluster was annotated if it had sufﬁcient
reads to exceed a Bonferroni-corrected Po10e 4 using both frequencies against
the Poisson distribution
De novo motif analysis. Motif analysis was performed as previously described48.
Brieﬂy, HOMER49 was used to call de novo motifs using the command
‘ﬁndMotifs.pl oforeground4 fasta ooutloc4 -nofacts –p 4 –rna –S 20 –len
5,6,7,8,9 –noconvert –nogo –fasta obackground4. Foreground is deﬁned as a
fasta ﬁle of sequences taken from all called clusters, or all called clusters in a speciﬁc
transcriptome region and background was randomly located clusters within the
same genic regions as predicted TAF15 clusters.
Peak annotations. Transcriptome regions and gene classes were deﬁned using
annotations found in GENCODE version 17 (ref. 50). Depending on the analysis,
clusters were either associated by the GENCODE-annotated 50 UTR, 30 UTR, exon
or intronic regions. If a cluster overlapped multiple regions or a single part of a
transcript was annotated as multiple regions, clusters were iteratively assigned ﬁrst
as exon, then 30 UTR, 50 UTR and ﬁnally as proximal or distal introns (as deﬁned
as 500 bp or greater from an exon–intron boundary). Overlapping peaks were
calculated using bedtools51,52.
Enrichment of peaks relative to region size. To compute the fold enrichment of
peaks in a given region, the fraction of peaks in that region was calculated as
described above. The fractional region size was derived by dividing the total
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number of base pairs in that region relative to the total number of base pairs in all
regions. Fold enrichment was computed using the equation log2 (FCLIP/Fregion).
Distance of peaks from motifs. Distance from peaks was computed by using the
annotatePeaks function in HOMER49 with the arguments ‘annotatePeaks.pl
opeaks4 mm9 -momotif4, -hist 10-size 1000 –noann’. Identiﬁcation of peaks
and motifs was determined as described above.
RBNS. RBNS was performed as previously described26. Brieﬂy, truncated reading
frames of FUS (amino acids 204–415) and TAF15 (amino acids 235–418), which
contain all RNA-binding domains, were cloned downstream of a tandem GST-SBP
tag into a modiﬁed pGex6p-1 vector (GE). Truncated proteins were recombinantly
expressed and puriﬁed via the GST tag, and used for RBNS, which was performed
at 5 concentrations (0, 5, 20, 80 and 320 nM) with a pool of randomized 20mer
RNAs, ﬂanked by short primers. Preparation of the randomized RNA pool and all
reaction conditions was identical to previous descriptions26. Further computational
analysis details can be found in Supplementary Methods.
RNA-seq library preparation and analysis. Total RNA was extracted from
mouse tissues and human cells using TRIzol (Invitrogen) according to the man-
ufacturer’s instructions. Total RNA (0.5–3 mg) was DNase-treated
and subjected to poly(A) selection or Ribo-Zero treatment followed by library
preparation using TruSeq Stranded mRNA and Total RNA Sample Preparation Kit
(Illumina). Barcoded libraries were pooled at equal concentrations and sequenced
on the HiSeq2000 or HiSeq2500 platform for 50 cycles. RNA-seq reads were
trimmed of polyA tails, adapters and low-quality ends using Cutadapt53 with
parameters --match-read-wildcards --times 2 -e 0 -O 5 --quality-cutoff’ 6 -m 18 -b
TCGTATGCCGTCTTCTGCTTG -bATCTCGTATGCCGTCTTCTGCTTG -bC
GACAGGTTCAGAGTTCTACAGTCCGACGATC -bTGGAATTCTCGGGTG
CCAAGG -bAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAA -bTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTT. Reads were then mapped against a database of repetitive
elements derived from RepBase (version 18.05) using Bowtie (version 1.0.0) with
parameters -S -q -p 16 -e 100 -l 20 (ref. 54). Reads that did not map to
Repbase sequences were aligned to the hg19 human genome (UCSC assembly)
using STAR (version 2.3.0e)55 with parameters --outSAMunmapped Within –
outFilterMultimapNmax 10 –outFilterMultimapScoreRange 1. Counts were
calculated with featureCounts56 and reads per kilobase of transcript per million
(RPKM) were computed. Differential expression was calculated using DESeq2 (ref. 57),
individually pairing each knockdown experiments with their respective controls.
Test of overlapping signiﬁcance between gene sets. Genes from each differ-
ential expression experiment were considered signiﬁcant if |log2 fold change|
o log2(1.5) and the adjusted Po0.05. Signiﬁcant genes between two sets were
overlapped and the total set of genes was deﬁned as genes that were expressed
(RPKM41) in the corresponding control experiment. A hypergeometic test was
performed to determine whether the overlap of two gene sets was statistically
signiﬁcant. Regression analysis was performed using the scipy linear regression
function on genes that were signiﬁcantly differentially expressed in both samples.
RT–PCR of splicing events. To validate AS events, RT–PCR (24–27 ampliﬁcation
cycles) was carried out using poly-A-selected and reverse-transcribed (Superscript
III, Invitrogen) cDNA from mice (n¼ 3) treated with either a control ASO or ASO
targeting the indicated RBP. Isoform products were visualized using the Agilent
2200 TapeStation System (Agilent Technologies) or on an agarose gel and quan-
tiﬁed using ImageJ to calculate ratios between inclusion and exclusion products.
Statistical signiﬁcance in differences between control and ASO samples was cal-
culated by Student’s t-test. Primer sequences are listed in Supplementary Data 9.
qRT–PCR. qRT–PCR was performed using Power SYBR Green Master Mix
(Life Technologies) using poly-A-selected and reverse-transcribed (Superscript III,
Invitrogen) cDNA on an iQ5 real-time PCR detection system (Bio-Rad). For each
biological replicate, qRT–PCR was carried out in technical triplicates. GAPDH and
Actin were used as reference genes for human and mouse targets, respectively.
Analysis was performed using the iQ5 optical system software (Bio-Rad; version
2.1). Expression values were normalized to the reference gene, and expression
values were expressed as a fold change relative to control samples. Intergroup
differences were assessed by two-tailed Student’s t-test. Primer sequences were
designed using the Primer3 software58 or obtained from PrimerBank59. Primer
sequences are listed in Supplementary Data 9.
RNA immunoprecipitation qPCR. NPCs were resuspended in lysis buffer (50mM
Tris pH 7.4, 100mM NaCl, 1% NP-40, 0.1% SDS and 0.5% sodium deoxycholate)
supplemented with 1 Protease Inhibitor cocktail (Roche) and 80U of RNAse
Inhibitor (Roche). Clariﬁed lysates were pre-cleared with Protein G agarose beads
(Life Technologies). Aliquots of the supernatant (equivalent to 5% of supernatant)
were saved as input protein and RNA. The remainder of the supernatant was
incubated with 10mg of antibody at 4 C for 4 h. The protein–RNA–antibody
complex was precipitated by incubation with Protein G magnetic beads overnight
at 4 C. Beads were washed twice with lysis buffer and three times with wash buffer
(5mM Tris pH 7.5, 150mM NaCl, 0.1% Triton X-100). Ten per cent of the bead
slurry was reserved for western blot analysis. The remaining bead slurry was
resuspended in TRIzol (Life Technologies), and RNA was extracted as per the
manufacturer’s instructions. Input and immunoprecipitated RNA was converted
into cDNA and gene expression was measured with qPCR. RNA immunopreci-
pitation qPCR studies were performed in biological duplicates. Primer sequences
are listed in Supplementary Data 9.
Antibodies for western blot analysis. The primary antibodies used are as follows:
FUS/TLS (ProteinTech 1:1,000), FUS/TLS (Santa Cruz Biotechnology, clone 4H11,
sc-47711, 1:100), TAF15 (Bethyl Laboratories 300A-308, 1:1,000), TDP-43
(Proteintech, 10782, 1:2,000) and GAPDH (Abcam, AB8245, 1:10,000). Images
have been cropped for presentation. Full-size images are presented in
Supplementary Fig. 8.
Immunoﬂuorescence. Cells were ﬁxed in 4% paraformaldehyde for 20min,
washed three times in PBS and simultaneously blocked and permeabilized with
5% donkey serum and 0.1% Triton X-100 in PBS for 1 h at room temperature. Cells
were then rinsed once in PBS and incubated with primary antibody overnight at
4 C. After ﬁve washes with PBS, secondary antibodies consisting of goat anti-
rabbit Alexa Fluor 488 and goat anti-mouse Alexa Fluor 555 (Life Technologies)
were added at a dilution of 1:1,000 for 2 h at room temperature. Following incu-
bation, the cells were rinsed three times with PBS, and nuclei were labelled with
1 mgml 1 4,6-diamidino-2-phenylindole for 10min. The following primary anti-
bodies were used: HB9 (1:100, DSHB), Islet1 (1:500, Santa Cruz Biotechnology),
Oct4 (1:500, Cell Signaling), Olig2 (1:500, Millipore), Sox2 (1:500, Cell Signaling),
Tra1-60 (1:1,000, Millipore), Tra1-81 (1:1,000, Millipore) and Tuj1 (1:500,
Millipore).
RBNS computational analysis. RBNS analysis was performed as previously
described60. Brieﬂy, motif enrichment (R) values were calculated for 6mers as the
motif frequency in the RBP-selected pool over the frequency in the input RNA
library. R values were considered signiﬁcant if they had a Z-score Z 2 (mean and
s.d. calculated over all 6mers). Values in Fig. 2 and Supplementary Fig. 2 are for the
protein concentration library with the highest overall enrichment (80 nM for both
proteins). RBNS data sets have been deposited at the ENCODE DCC under
accession IDs ENCSR936LOF for FUS and ENCSR827QYL for TAF15.
Motif logos were generated following an iterative procedure on the most
enriched 6mer library precipitated from the GST-SBP-tagged protein: the most
enriched 6mer was given a weight equal to its enrichment over the input library
(¼R 1), and all occurrences of that 6mer were masked in both the precipitated
and input libraries. All enrichments were recalculated on the masked read sets to
obtain the most enriched remaining 6mer and its corresponding weight, with this
process continuing until the R Z-score was less than 2. All 6mers determined from
this procedure were aligned to minimize mismatches to the most enriched 6mer,
and a new motif was generated if the number of mismatches was greater than 2.
The frequencies of each nucleotide in the position weight matrix, as well as the
overall percentage of each motif, were determined from the weights of the
individual aligned 6mers that went into that motif.
For comparison with CLIP-seq data, RBNS enrichments were determined from
the concentration with the largest enrichment. For enrichment in CLIP-seq 6mers,
FASTQ sequences were extracted from all clusters, and a matched number of
random clusters from the same genomic region (50 UTR, exon, 30 UTR, proximal
introns and distal introns). EMBOSS compseq was performed on the real and
background set, and a delta between real and background k-mers was calculated
with the equation:
Dkmer ¼
fCLIP
NCLIP
 fbackgroundNbackground
1
NCLIP
þ 1Nbackground
 
g 1 gð Þ
 q ; for g ¼ fCLIP þ fbackground
NCLIP þNbackground
where N is the number of times the motif occurs in the set and f is observed
frequency of the motif. To plot enrichment, all 6mers with the 4mer of interest
were highlighted and a KDE plot was created for all 6mers. The Kolmogorov–
Smirnov two-tailed test determined statistical signiﬁcance in differences between
distributions.
RNA stability analysis. NPCs were infected with virus as described above. Ninety-
six hours post infection, cells were treated with Actinomycin D (10 mgml 1) for
the indicated times. Cells were washed with cold PBS and harvested for RNA
extraction using TRIzol (Life Technologies) or protein for western blot analysis.
One microgram of total RNA was subjected to DNase treatment and poly(A)
enrichment, and was used to prepare RNA-seq libraries as described above. To
calculate RNA half-lives, RPKMs from each experiment were calculated and decay
rates were generated by ﬁtting RPKMs for each gene to a log-linear regression
using the equation Ln N tð Þð Þ ¼ ln N0ð Þþ  lt , where t is time and N(t) is the
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RPKM at time t. Half-lives were derived from the decay rate using the equation
t1/2¼ ln(2)/l. Genes were included in the analysis if their decay rate was positive
(that is, RPKMs decreased over time) and the linear regression line had a R2 ﬁt
greater than 0.6.
Correlation of gene expression to CLIP binding and motifs. Mouse brain CLIP-
seq data for FUS and TDP-43 were previously described21,22. The binding location
of each peak was assigned using the peak annotation method as described above.
For each RBP, mouse brain CLIP-seq data and mouse striatum knockdown
RNA-seq data were used to classify genes into the following categories: target and
regulated, non-target and regulated, target and not regulated, and non-target and
not regulated. A Fisher’s exact test was performed to determine whether binding
and regulation were signiﬁcantly correlated. Motif analysis was performed similarly
by determining whether a TAF15 ‘GGUAA’ or FUS ‘GUGG’ motif was present in
the 30 UTRs or introns of genes.
Splicing-sensitive microarray analysis. Total RNA from three individual control
and TAF15 ASO-treated mice were prepared for hybridization to splicing-sensitive
microarrays (Affymetrix). Separation scores (Sep scores) were generated as
previously described61. For clustering of splicing events, a splicing event was
included in clustering if, for any of the three experiments, TAF15, FUS or TDP-43
knockdown was signiﬁcantly (|Sep score|40.5, q valueo0.05) differentially
expressed. Hierarchal clustering was performed using Seaborn/SciPy on the Sep
scores for each splicing event. Overlap analysis of splicing-sensitive microarray
results and TAF15 mouse CLIP-seq data was performed as previously described61.
GO analysis. Signiﬁcantly enriched GO terms were identiﬁed using a hypergeo-
metric test that compared the number of genes that were either regulated
(RNA-seq data) or bound (CLIP-seq data) in each GO term to genes expressed
(background) in each GO term. The background gene set was deﬁned as genes that
were expressed (RPKM41) in the corresponding control experiment.
Data availability. The accession number for the sequencing data deposited in
GEO for this paper is GSE77707.
References
1. Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative
inclusions in frontotemporal lobar degeneration and amyotrophic lateral
sclerosis. Biochem. Biophys. Res. Commun. 351, 602–611 (2006).
2. Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar
degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006).
3. Corrado, L. et al. High frequency of TARDBP gene mutations in Italian
patients with amyotrophic lateral sclerosis. Hum. Mutat. 30, 688–694 (2009).
4. Daoud, H. et al. Contribution of TARDBP mutations to sporadic amyotrophic
lateral sclerosis. J. Med. Genet. 46, 112–114 (2009).
5. Del Bo, R. et al. TARDBP (TDP-43) sequence analysis in patients with familial
and sporadic ALS: identiﬁcation of two novel mutations. Eur. J. Neurol. 16,
727–732 (2009).
6. Ku¨hnlein, P. et al. Two German kindreds with familial amyotrophic lateral
sclerosis due to TARDBP mutations. Arch. Neurol. 65, 1185–1189 (2008).
7. Lemmens, R. et al. TDP-43 M311V mutation in familial amyotrophic lateral
sclerosis. J. Neurol. Neurosurg. Psychiatry 80, 354–355 (2009).
8. Rutherford, N. J. et al. Novel mutations in TARDBP (TDP-43) in patients with
familial amyotrophic lateral sclerosis. PLoS Genet. 4, e1000193 (2008).
9. Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic
lateral sclerosis. Science 319, 1668–1672 (2008).
10. Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial
amyotrophic lateral sclerosis type 6. Science 323, 1208–1211 (2009).
11. Kwiatkowski, T. J. J. et al. Mutations in the FUS/TLS gene on chromosome 16
cause familial amyotrophic lateral sclerosis. Science 323, 1205–1208 (2009).
12. Lagier-Tourenne, C., Polymenidou, M. & Cleveland, D. W. TDP-43 and
FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum.
Mol. Genet. 19, R46–R64 (2010).
13. Couthouis, J. et al. A yeast functional screen predicts new candidate ALS
disease genes. Proc. Natl Acad. Sci. USA 108, 20881–20890 (2011).
14. Ticozzi, N. et al. Mutational analysis reveals the FUS homolog TAF15 as a
candidate gene for familial amyotrophic lateral sclerosis. Am. J. Med. Genet. B
Neuropsychiatr. Genet 156B, 285–290 (2011).
15. Ibrahim, F. et al. Identiﬁcation of in vivo, conserved, TAF15 RNA binding sites
reveals the impact of TAF15 on the neuronal transcriptome. Cell Rep. 3,
301–308 (2013).
16. Neumann, M. et al. FET proteins TAF15 and EWS are selective markers that
distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with
FUS mutations. Brain 134, 2595–2609 (2011).
17. Vance, C. et al. ALS mutant FUS disrupts nuclear localization and sequesters
wild-type FUS within cytoplasmic stress granules. Hum. Mol. Genet. 22,
2676–2688 (2013).
18. Guo, W. et al. An ALS-associated mutation affecting TDP-43 enhances protein
aggregation, ﬁbril formation and neurotoxicity. Nat. Struct. Mol. Biol. 18,
822–830 (2011).
19. Schwartz, J. C., Cech, T. R. & Parker, R. R. Biochemical properties and
biological functions of FET proteins. Annu. Rev. Biochem. 84,
141210135300003 (2014).
20. Rogelj, B. et al. Widespread binding of FUS along nascent RNA regulates
alternative splicing in the brain. Sci. Rep. 2, 603 (2012).
21. Lagier-Tourenne, C. et al. Divergent roles of ALS-linked proteins FUS/TLS and
TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci. 15, 1488–1497
(2012).
22. Polymenidou, M. et al. Long pre-mRNA depletion and RNA missplicing
contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 14,
459–468 (2011).
23. Thomsen, C., Grundevik, P., Elias, P., Ståhlberg, A. & Aman, P. A conserved
N-terminal motif is required for complex formation between FUS, EWSR1,
TAF15 and their oncogenic fusion proteins. FASEB J. 27, 4965–4974 (2013).
24. Sun, S. et al. ALS-causative mutations in FUS/TLS confer gain and loss of
function by altered association with SMN and U1-snRNP. Nat. Commun. 6,
6171 (2015).
25. Shapiro, M. B. & Senapathy, P. RNA splice junctions of different classes of
eukaryotes: sequence statistics and functional implications in gene expression.
Nucleic Acids Res. 15, 7155–7174 (1987).
26. Lambert, N. et al. RNA Bind-n-Seq: quantitative assessment of the sequence
and structural binding speciﬁcity of RNA binding proteins. Mol. Cell 54,
887–900 (2014).
27. Yang, L. et al. Subcellular localization and RNAs determine FUS architecture in
different cellular compartments. Hum. Mol. Genet. 24, 5174–5183 (2015).
28. Hoell, J. I. et al. RNA targets of wild-type and mutant FET family proteins. Nat.
Struct. Mol. Biol. 18, 1428–1431 (2011).
29. Wang, E. T. et al. Alternative isoform regulation in human tissue
transcriptomes. Nature 456, 470–476 (2008).
30. Licatalosi, D. D. et al. HITS-CLIP yields genome-wide insights into brain
alternative RNA processing. Nature 456, 464–469 (2008).
31. Olszewski, P. K. et al. Neurobeachin, a regulator of synaptic protein targeting, is
associated with body fat mass and feeding behavior in mice and body-mass
index in humans. PLoS Genet. 8, e1002568 (2012).
32. Jobert, L. et al. Human U1 snRNA forms a new chromatin-associated snRNP
with TAF15. EMBO Rep. 10, 494–500 (2009).
33. Yamazaki, T. et al. FUS-SMN protein interactions link the motor neuron
diseases ALS and SMA. Cell Rep. 2, 799–806 (2012).
34. Tollervey, J. R. et al. Characterizing the RNA targets and position-dependent
splicing regulation by TDP-43. Nat. Neurosci. 14, 452–458 (2011).
35. Mu¨ller-Hartmann, H. et al. The human 20-kDa 5’-(CGG)(n)-3’-binding
protein is targeted to the nucleus and affects the activity of the FMR1 promoter.
J. Biol. Chem. 275, 6447–6452 (2000).
36. Chambers, S. M. et al. Highly efﬁcient neural conversion of human ES and iPS
cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27, 275–280 (2009).
37. Batra, R. et al. Gene Expression Signatures of Sporadic ALS Motor Neuron
Populations. bioRxiv (Cold Spring Harbor Labs Journals, 2016).
38. Ameur, A. et al. Total RNA sequencing reveals nascent transcription and
widespread co-transcriptional splicing in the human brain. Nat. Struct. Mol.
Biol. 18, 1435–1440 (2011).
39. Schwartz, J. C. et al. FUS binds the CTD of RNA polymerase II and regulates its
phosphorylation at Ser2. Genes Dev. 26, 2690–2695 (2012).
40. Kwon, I. et al. Phosphorylation-regulated binding of RNA polymerase II to
ﬁbrous polymers of low-complexity domains. Cell 155, 1049–1060 (2013).
41. Bertolotti, A., Lutz, Y., Heard, D. J., Chambon, P. & Tora, L. hTAF(II)68, a
novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins
TLS/FUS and EWS is associated with both TFIID and RNA polymerase II.
EMBO J. 15, 5022–5031 (1996).
42. Sharma, A. et al. ALS-associated mutant FUS induces selective motor neuron
degeneration through toxic gain of function. Nat. Commun. 7, 10465 (2016).
43. Sephton, C. F. et al. Activity-dependent FUS dysregulation disrupts synaptic
homeostasis. Proc. Natl Acad. Sci. USA 111, E4769–E4778 (2014).
44. Budini, M. & Buratti, E. TDP-43 autoregulation: implications for disease.
J. Mol. Neurosci. 45, 473–479 (2011).
45. Polymenidou, M. et al. Misregulated RNA processing in amyotrophic lateral
sclerosis. Brain Res. 1462, 3–15 (2012).
46. Rigo, F. et al. Pharmacology of a central nervous system delivered 2’-O-
methoxyethyl-modiﬁed survival of motor neuron splicing oligonucleotide in
mice and nonhuman primates. J. Pharmacol. Exp. Ther. 350, 46–55 (2014).
47. Yeo, G. W. et al. An RNA code for the FOX2 splicing regulator revealed by
mapping RNA-protein interactions in stem cells. Nat. Struct. Mol. Biol. 16,
130–137 (2009).
48. Lovci, M. T. et al. Rbfox proteins regulate alternative mRNA splicing through
evolutionarily conserved RNA bridges. Nat. Struct. Mol. Biol. 20, 1434–1442
(2013).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12143 ARTICLE
NATURE COMMUNICATIONS | 7:12143 |DOI: 10.1038/ncomms12143 | www.nature.com/naturecommunications 13
49. Heinz, S. et al. Simple combinations of lineage-determining transcription
factors prime cis-regulatory elements required for macrophage and B cell
identities. Mol. Cell 38, 576–589 (2010).
50. Harrow, J. et al. GENCODE: the reference human genome annotation for The
ENCODE Project. Genome Res. 22, 1760–1774 (2012).
51. Quinlan, A. R. & Hall, I. M. BEDTools: a ﬂexible suite of utilities for comparing
genomic features. Bioinformatics 26, 841–842 (2010).
52. Dale, R. K., Pedersen, B. S. & Quinlan, A. R. Pybedtools: a ﬂexible Python
library for manipulating genomic datasets and annotations. Bioinformatics 27,
3423–3424 (2011).
53. Martin, M. Cutadapt removes adapter sequences from high-throughput
sequencing reads. EMBnet J. 17, 10–12 (2011).
54. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-
efﬁcient alignment of short DNA sequences to the human genome. Genome
Biol. 10, R25 (2009).
55. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29,
15–21 (2013).
56. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efﬁcient general purpose
program for assigning sequence reads to genomic features. Bioinformatics 30,
923–930 (2014).
57. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
58. Untergasser, A. et al. Primer3--new capabilities and interfaces. Nucleic Acids
Res. 40, e115 (2012).
59. Wang, X., Spandidos, A., Wang, H. & Seed, B. PrimerBank: a PCR primer
database for quantitative gene expression analysis, 2012 update. Nucleic Acids
Res. 40, D1144–D1149 (2012).
60. Conway, A. E. et al. Enhanced CLIP uncovers IMP protein-RNA targets in
human pluripotent stem cells important for cell adhesion and survival. Cell Rep.
15, 666–679 (2016).
61. Huelga, S. C. et al. Integrative genome-wide analysis reveals cooperative
regulation of alternative splicing by hnRNP proteins. Cell Rep. 1, 167–178
(2012).
Acknowledgements
We thank members of the Yeo lab, especially Stefan Aigner, for critical reading of the
manuscript. S.C.H. and G.A.P. were funded by National Science Foundation Graduate
Research Fellowships. G.A.P. was also partially supported by the National Institute of
General Medical Sciences of the National Institutes of Health under Award Number
T32GM008666. This work was supported by grants from the National Institutes of
Health (HG004659, NS075449 and HG007005 to G.W.Y; NS077284 to H.Z.), the Cali-
fornia Institute of Regenerative Medicine (RB3-05009 and RB4-06045 to G.W.Y.) and
ALS Association (VC8K27 to G.W.Y.; 6SE340 to H.Z.). This work was partially sup-
ported by NIH grant HG007005 to C.B.B. We thank Ionis Pharmaceuticals for sharing
reagents and unpublished results. G.W.Y. is an Alfred P. Sloan Research Fellow.
Author contributions
G.W.Y. conceived the study. S.C.H., J.P.D., L.S. and M.A. performed splicing microarray
analyses. P.F., N.J.L. and C.B.B. performed the RBNS experiments. T.Y.L. performed the
CLIP experiments. A.Q.V., F.J.M., J.C. and K.K. generated iPSC lines and performed
neural differentiation. B.S. assisted with the RNA stability experiments. K.R.H. and G.P.
performed the bioinformatics analyses. F.R. and S.C.H. performed the antisense-oligo-
nucleotide experiments. H.Z., J.Z., F.C. and E.K. provided the FUS R521G ﬁbroblasts.
R.B. and J.R. contributed sporadic ALS and control patient RNA-seq data and analyses.
K.K., G.A.P. and G.W.Y. analysed data and wrote the manuscript.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: F.R. is a paid employee of Ionis Pharmaceuticals. The
remaining authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Kapeli, K. et al. Distinct and shared functions of ALS-associated
proteins TDP-43, FUS and TAF15 revealed by multisystem analyses. Nat. Commun.
7:12143 doi: 10.1038/ncomms12143 (2016).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2016
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12143
14 NATURE COMMUNICATIONS | 7:12143 | DOI: 10.1038/ncomms12143 | www.nature.com/naturecommunications
